These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pathophysiological changes of inflammatory syndrome in multiple sclerosis after instituting therapeutic plasmapheresis. Vlaic S; Poalelungi V; Bălăeţ M; Purcărea VL; Bălăeţ C; Coculescu BI J Med Life; 2017; 10(1):50-53. PubMed ID: 28255377 [TBL] [Abstract][Full Text] [Related]
5. Plasmapheresis in multiple sclerosis: prospective trial of pheresis and immunosuppression versus immunosuppression alone. Tindall RS; Walker JE; Ehle AL; Near L; Rollins J; Becker D Neurology; 1982 Jul; 32(7):739-43. PubMed ID: 7201110 [TBL] [Abstract][Full Text] [Related]
6. Removal of valproic acid by plasmapheresis in a patient treated for multiple sclerosis. Bastiaans DE; van Uden IW; Ruiterkamp RA; de Jong BA Ther Drug Monit; 2013 Feb; 35(1):1-3. PubMed ID: 23222689 [TBL] [Abstract][Full Text] [Related]
7. [Plasmapheresis: its use in multiple sclerosis and other demyelinating processes of the central nervous system. An observation study]. Meca-Lallana JE; Rodríguez-Hilario H; Martínez-Vidal S; Saura-Luján I; Carretón-Ballester A; Escribano-Soriano JB; Martín-Fernández J; Genovés-Aleixandre A; Mateo-Bosch E; Fernández-Barreiro A Rev Neurol; 2003 Nov 16-30; 37(10):917-26. PubMed ID: 14634919 [TBL] [Abstract][Full Text] [Related]
8. Successful immunoadsorption with membrane plasmapheresis for multiple sclerosis. Hosokawa S; Oyamaguchi A; Yoshida O ASAIO Trans; 1989; 35(3):576-7. PubMed ID: 2688722 [TBL] [Abstract][Full Text] [Related]
9. Natural killer cell activity in patients with multiple sclerosis: interferon and plasmapheresis. Uchida A; Maida EM; Lenzhofer R; Micksche M Immunobiology; 1982 Feb; 160(5):392-402. PubMed ID: 6175561 [TBL] [Abstract][Full Text] [Related]
10. [Successful treatment with additional plasmapheresis for the exacerbation of acute neurological symptoms in a girl with multiple sclerosis]. Mogami Y; Yamada K; Toribe Y; Yanagihara K; Mano T; Suzuki Y No To Hattatsu; 2011 Jan; 43(1):36-40. PubMed ID: 21400930 [TBL] [Abstract][Full Text] [Related]
11. Plasmapheresis in multiple sclerosis: preliminary findings. Dau PC; Petajan JH; Johnson KP; Panitch HS; Bornstein MB Neurology; 1980 Oct; 30(10):1023-8. PubMed ID: 6448360 [TBL] [Abstract][Full Text] [Related]
12. Interferon inhibitor factor predicting success of plasmapheresis in patients with multiple sclerosis. Medenica RD; Mukerjee S; Huschart T; Corbitt W J Clin Apher; 1994; 9(4):216-21. PubMed ID: 7759466 [TBL] [Abstract][Full Text] [Related]
13. Neuroelectric blocking factors in multiple sclerosis and normal human sera. Seil FJ; Leiman AL; Kelly JM Arch Neurol; 1976 Jun; 33(6):418-22. PubMed ID: 938266 [TBL] [Abstract][Full Text] [Related]
14. Plasmapheresis and immunoadsorption in patients with steroid refractory multiple sclerosis relapses. Faissner S; Nikolayczik J; Chan A; Hellwig K; Gold R; Yoon MS; Haghikia A J Neurol; 2016 Jun; 263(6):1092-8. PubMed ID: 27039388 [TBL] [Abstract][Full Text] [Related]
15. [Plasmapheresis in multiple sclerosis]. Fuchs S; Pogglitsch H; Ladurner G; Lechner H Wien Klin Wochenschr; 1984 Jan; 96(2):67-9. PubMed ID: 6710999 [TBL] [Abstract][Full Text] [Related]
19. Trace elements and plasmapheresis. Hosokawa S; Oyamaguchi A; Yoshida O Int J Artif Organs; 1991 Apr; 14(4):242-5. PubMed ID: 2060990 [TBL] [Abstract][Full Text] [Related]
20. Plasmapheresis, lymphocytapheresis, and immunosuppressive drug therapy in multiple sclerosis. Hauser SL; Fosburg M; Kevy S; Weiner HL Prog Clin Biol Res; 1982; 106():239-54. PubMed ID: 6184727 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]